Why the study?
Does ethyl-ester omega-3 fatty acid reduce triglyceride serum levels in Taiwanese patients with hypertriglyceridemia?
RCT (n=253)
Double-blind
1:1:1 ratio
Yes
Does ethyl-ester omega-3 fatty acid reduce triglyceride serum levels in Taiwanese patients with hypertriglyceridemia?
Ethyl-ester omega-3 fatty acid at 2 g/day and 4 g/day significantly reduces serum triglyceride levels in Taiwanese patients with hypertriglyceridemia, offering a safe and effective treatment option.
Answers are grounded in this paper and cite their sources.
Supports Omacor for triglyceride reduction; confirms efficacy of 2-4 g/day dosing versus placebo in RCT.
AIM: , a prescription ethyl-ester omega-3 fatty acid for the treatment of hypertriglyceridemia, administered at doses of 2 g/day and 4 g/day to Taiwanese hypertriglyceridemic patients. METHODS: ) or placebo, for eight weeks. The primary endpoint was the percentage change in triglyceride serum levels from baseline to the end of treatment. RESULTS: 2 g/day, and placebo groups, respectively. No drug-related serious adverse events were reported during the study. CONCLUSIONS: may be a feasible option to treat hypertriglyceridemia in Taiwanese patients.
No takes yet. Share an insight, caveat, or question.
Su et al. (2016) conducted an RCT in Hypertriglyceridemia (n=253). Omacor (ethyl-ester omega-3 fatty acid) vs. Placebo was evaluated on Percentage change in triglyceride serum levels from baseline to week 8 (p=<0.0001).
Synapse has enriched 10 related papers. Consider them for comparative context: